# Scilex Holding Company (SCLX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $95,995.8  
**Price:** $8.70 (-1.14%)

> Scilex Holding Company is an innovative biopharmaceutical firm focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain treatment. Its portfolio features ZTLido, a proprietary patch with advanced adhesion and delivery technology for optimized transdermal drug transport to localized pain areas; Elyxyb, the only liquid ready-to-use oral solution providing fast, long-lasting migraine relief; and Gloperba, an anti-inflammatory oral solution enabling precision dosing for high-risk patients. Headquartered in Palo Alto, California, and founded in 2020, the company employs 115 people under CEO Henry H. Ji and operates subsidiaries Scilex Pharmaceuticals and Semnur Pharmaceuticals. Scilex Holding Company generates revenue through these specialized therapies, emphasizing ethical principles in social, environmental, economic, and pharmaceutical development to enhance patient quality of life and position itself as a leader in the non-opioid pain sector.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $30M | $126M | -$346M | -$374M | $-36.48 |
| 2024 | $57M | $167M | -$83M | -$73M | $-8.05 |
| 2023 | $47M | $31M | -$105M | -$114M | $-1.28 |
| 2022 | $38M | $27M | -$51M | -$23M | $-0.17 |
| 2021 | $31M | $28M | -$36M | -$88M | $-0.67 |
| 2020 | $24M | $21M | -$35M | -$48M | $-0.36 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $365M | $577M | -$208M | $5M | — |
| 2024 | $93M | $286M | -$193M | $3M | — |
| 2023 | $101M | $274M | -$173M | $4M | — |
| 2022 | $87M | $50M | $36M | $2M | — |
| 2021 | $78M | $302M | -$224M | $4M | $72M |
| 2020 | $199,484 | $180,760 | $18,724 | $30,511 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $4M | $133,000 | $4M |
| 2024 | $19M | — | $19M |
| 2023 | -$21M | $30,000 | -$21M |
| 2022 | -$21M | $7,000 | -$21M |
| 2021 | -$29M | — | -$29M |
| 2020 | -$31M | $25,000 | -$31M |

Source: [CompaniesByCap](https://companiesbycap.com/company/SCLX)